Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859

被引：15

作者：

Qiu, YH ^{[1
]}

Bhattacharjee, S ^{[1
]}

Kraft, P ^{[1
]}

John, TM ^{[1
]}

Craig, E ^{[1
]}

Haynes-Johnson, D ^{[1
]}

Guan, JH ^{[1
]}

Jiang, WQ ^{[1
]}

Macielag, M ^{[1
]}

Sui, ZH ^{[1
]}

Clancy, J ^{[1
]}

Lundeen, S ^{[1
]}

机构：

[1] RW Johnson & Johnson Pharmaceut Res & Dev Inst, Drug Discovery, Reprod Therapeut, Raritan, NJ 08869 USA

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 2003年 / 472卷 / 1-2期

关键词：

phosphodiesterase; phosphodiesterase type 5 inhibitor; erectile dysfunction; corpus cavernosum;

D O I：

10.1016/S0014-2999(03)01868-5

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

We have characterized a novel, potent, and selective phosphodiesterase type 5 inhibitor, JNJ-10258859 ((R)-(-)-3-(2,3-dihydrobenzofuran-5-yl)-2-[5-(4-methoxy-phenyl)-pyrimidin-2-yl]-1,2,3,4-tetrahydro-pyrrolo[3,4-b]quinolin-9-one). Its inhibitory effects on phosphodiesterase 1-6 were determined using enzymes partially purified from human tissues. The compound inhibited phosphodiesterase type 5 with a K-i of 0.23 nM and displayed excellent selectivity versus phosphodiesterase types 1-4 (greater than or equal to 22,000 fold compared to phosphodiesterase type 5). It had 27-fold selectivity over phosphodiesterase type 6 as well. In a cell-based assay, JNJ-10258859 was more potent than sildenafil in potentiating nitric oxide (NO) induced accumulation of intracellular cGMP. The in vivo effect of JNJ-10258859 was evaluated in an anesthetized dog model via intravenous administration. The compound had similar efficacy to sildenafil in enhancing both the amplitude and duration of intracavernosal pressure increase induced by electrical stimulation to the pelvic nerve. No significant effects on either mean aortic pressure or heart rate were observed during the course of the experiments. This data suggests that JNJ-10258859 could be a useful treatment for erectile dysfunction. (C) 2003 Elsevier Science B.V. All rights reserved.

引用

页码：73 / 80

页数：8

共 28 条

[21] IC-351 -: Treatment of erectile dysfunction -: Treatment of female sexual dysfunction -: Phosphodiesterase 5 inhibitor [J].